• news.cision.com/
  • Sectra/
  • Geneva University Hospital in Switzerland to use Sectra’s digital pathology solution for full-scale primary diagnostics

Geneva University Hospital in Switzerland to use Sectra’s digital pathology solution for full-scale primary diagnostics

Report this content

Linköping, Sweden – March 2, 2020 – International medical imaging IT and cybersecurity company Sectra (STO: SECT B) has signed a digital pathology contract with Geneva University Hospital (Hôpitaux Universitaires de Genève) in Switzerland. A digital workflow enables pathologists to review and collaborate around cases in a way that is not possible with a microscope. It reduces variation and increases efficiency in primary diagnostics, thereby improving areas such as cancer care.

Geneva University Hospital is the largest of five university hospitals in Switzerland.

With digital images of tissue samples instead of physical glass slides, pathologists are able to instantly access and share current and historical images and information between departments and hospitals. The digital solution provides pathologists with assistance at critical decision points, such as grading or performing more precise measurements. It also enables image analysis, which in turn reduces variation and improves the precision of tasks such as cell counting. Digital access also facilitates second opinions, external reading resources, and specialist consultations. 

The solution at Geneva University Hospital is integrated with the hospital’s laboratory information system (LIS). This will provide pathologists with a complete overview of the patient history in one application and enables workflow orchestration to drive the reporting workflow according to sub-specialties, rules, and priorities. The solution’s vendor-neutral approach also gave Geneva University Hospital the freedom to select the scanner vendor of their choice.

Sectra’s pathology solution is part of its enterprise imaging offering. It provides a unified strategy for all imaging needs, and improves patient outcomes while lowering operational costs. The scalable and modular solution supports the most image-intense departments—radiology, breast imaging, pathology, cardiology and orthopaedics. Being built on the same technical platform, customers can easily extend a departmental solution to create a comprehensive VNA. Read more about Sectra’s enterprise imaging solution and why Sectra PACS is “Best in KLAS” at https://www.sectra.com/medical/.

The contract between Geneva University Hospital and Sectra was signed during the third quarter of the fiscal year.

Meet Sectra at HIMSS and ECR 2020
Sectra’s enterprise imaging solution, including digital pathology, will be showcased at the HIMSS and ECR trade shows. Visit booth #6248 at HIMSS and #D11 at ECR to learn more about the solution.
Book a meeting at HIMSS >> 
Book a meeting at ECR >>

About Sectra
Sectra assists hospitals throughout the world to enhance the efficiency of care, and authorities and defense forces in Europe to protect society’s most sensitive information. Thereby, Sectra contributes to a healthier and safer society. The company was founded in 1978, has its head office in Linköping, Sweden, with direct sales in 19 countries, and operates through partners worldwide. Sales in the 2018/2019 fiscal year totaled SEK 1,413 million. The Sectra share is quoted on the Nasdaq Stockholm exchange. For more information, visit www.sectra.com.
 

For further information, please contact:
Dr. Torbjörn Kronander, CEO and President Sectra AB, +46 (0)705 23 52 27
Marie Ekström Trägårdh, Executive Vice President Sectra AB and President Sectra Imaging IT Solutions, +46 (0)708 23 56 10

Tags:

Subscribe

Media

Media

Quotes

The digital pathology solution from Sectra is easy to use. Its robustness is crucial since we use it for primary diagnostics and handle large volumes. The digital advantages and the possibilities for integrated diagnostics will enable us to meet future demands and continue to provide the best possible care for our patients.
Professor Laura Rubbia-Brandt, Head of the Pathology Department at Geneva University Hospital